The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.
 
Jing Wu
Research Funding - Cothera Bioscience (Inst); Merck (Inst); NE1 (Inst); ProLynx (Inst)
 
Kathleen Wall
No Relationships to Disclose
 
Kelly Fernandez
No Relationships to Disclose
 
Christine McGowan
No Relationships to Disclose
 
Jennifer Joyce Reyes
Stock and Other Ownership Interests - Altimmune; Medtronic; Moderna Therapeutics; Pfizer
 
Zachary Sergi
No Relationships to Disclose
 
Shaunak Sathe
No Relationships to Disclose
 
Brett Theeler
No Relationships to Disclose
 
Marta Penas-Prado
Employment - AstraZeneca
Research Funding - CRADA from ProLynx (Inst)
 
Byram Ozer
No Relationships to Disclose
 
Mark Gilbert
Honoraria - Beth Israel Deaconess Medical Center; George Washington University; Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - Khosen Bio
 
Javed Khan
No Relationships to Disclose
 
Jung Kim
No Relationships to Disclose
 
Manoj Tyagi
No Relationships to Disclose
 
Liqiang Xi
No Relationships to Disclose
 
Ying Yuan
Consulting or Advisory Role - Abbvie; Aktis Oncology; Amgen; Astellas Pharma; Bexion; BioNTech SE; BrainChildBio; Cassava Sciences; Century Therapeutics; Century Therapeutics; Cogent Medicine; GT Medical Technologies; HUTCHMED; Kyowa Kirin International; Merck; Mitsubishi Tanabe Pharma; NextCure; Ono Pharmaceutical; Ono Pharmaceutical; Sangamo Therapeutics; Schrodinger; SERVIER; Takeda; Umoja Biopharma; Vertex